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Abstract
Background: More than 70% of children with sickle cell disease (SCD) are born in sub-Saharan Africa where the prevalence
at birth of this disease reaches 2% or higher in some selected areas. There is a dearth of knowledge on comprehensive care
received by children with SCD in sub-Saharan Africa and its associated cost. Such knowledge is important for setting
prevention and treatment priorities at national and international levels. This study focuses on routine care for children with
SCD in an outpatient clinic of the Kilifi District Hospital, located in a rural area on the coast of Kenya.
Objective: To estimate the per-patient costs for routine SCD outpatient care at a rural Kenyan hospital.
Methods: We collected routine administrative and primary cost data from the SCD outpatient clinic and supporting
departments at Kilifi District Hospital, Kenya. Costs were estimated by evaluating inputs - equipment, medication, supplies,
building use, utility, and personnel - to reflect the cost of offering this service within an existing healthcare facility. Annual
economic costs were similarly calculated based on input costs, prorated lifetime of equipment and appropriate discount
rate. Sensitivity analyses evaluated these costs under different pay scales and different discount rate.
Results:We estimated that the annual economic cost per patient attending the SCD clinic was USD 138 in 2010 with a range
of USD 94 to USD 229.
Conclusion: This study supplies the first published estimate of the cost of routine outpatient care for children born with
SCD in sub-Saharan Africa. Our study provides policy makers with an indication of the potential future costs of maintaining
specialist outpatient clinics for children living with SCD in similar contexts.
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Background
Haemoglobinopathies are the most common single gene
disorder in the world [1] and 70% of children born with
haemoglobinopathies actually have sickle cell disease (SCD) [2].
More than 70% of children with SCD are born in sub-Saharan
Africa [1–3] where the prevalence at birth was estimated at 2% or
higher in some selected areas in Africa [4,5]. SCD is also the most
common genetic disorder in many developed countries such as the
United Kingdom and the United States of America, but with a
much lower birth prevalence of around 1 in 2000 [6] and 1 in
2500 [7] respectively. High rates of child morbidity and mortality
have long characterized the disease worldwide. More recently,
however, the introduction of newborn screening, and other
improvements in healthcare have all but eliminated SCD-related
excess childhood mortality in developed countries. Numerous
studies have been conducted in the developed countries on the
treatment of children and adults with SCD [8–13], and their
healthcare expenditures [14–16]. However, in sub-Saharan Africa,
only a few studies have focused on the comprehensive care of
children with SCD [17–19] and little is known on the cost of this
care. Such knowledge is important for setting prevention and
treatment priorities at national and international levels for at least
two reasons. First, the high percentage of SCD gene carriers —
which can reach up to 15% or 30% in many countries in sub-
Saharan Africa — indicates that SCD will remain common in the
foreseeable future [2]. Second, recent declines in infectious
diseases and increased awareness of SCD imply that children
born with the disease will increasingly survive the high mortality
infancy period and will use the healthcare system.
This study aims at filling a gap in knowledge of the utilisation of
medical services and the associated costs of the SCD outpatient
clinic in Kilifi District Hospital (KDH), in coastal Kenya. Through
this study we describe the routine utilization of the SCD outpatient
clinic at KDH between 2003 and 2010 and estimate its costs from
a provider perspective in 2010. Information presented here offers
potentially useful insights to those aiming to provide such services
in similar settings. This study represents the first step in estimating
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the total cost of the disease in the area, and the distribution of
those costs by families and providers.
Methods
Study setting
The study was conducted at the Kilifi District Hospital, located
on the Kenyan coast, which serves as a first-referral hospital to a
population of approximately 500,000 people who live in Kilifi and
the surrounding districts. KDH is the base for the Kenya Medical
Research Institute (KEMRI)/Welcome Trust Research Pro-
gramme where a diverse portfolio of research is conducted on a
platform consisting of clinical surveillance of the paediatric wards
linked to data from the Kilifi Health and Demographic
Surveillance System (KHDSS). KHDSS monitors a population
of approximately 250,000 living in an area of 891 km2 surround-
ing the Kilifi District Hospital that is home to around 80% of all
children admitted to the paediatric wards [20]. KHDSS provides
information on the resident population, its demographic charac-
teristics, births, migration, deaths and cause of death.
Kilifi District Hospital is the only hospital in the Coast region in
Kenya that provides specialist care to children with SCD. A
dedicated SCD outpatient clinic at Kilifi District Hospital has
existed for more than 20 years and data from this clinic have been
computerised since 2003. Clinical information on patients with
SCD served by this clinic in its first few years has been described
earlier [19]. The SCD outpatient clinic is held weekly on Ministry
of Health property by personnel employed by the Ministry or the
research programme. Laboratory and pharmacy departments
offering SCD-related services are staffed by the research
programme.
Costing perspective
We calculated economic costs of running the SCD outpatient
clinic at KDH in 2010 from a provider perspective by aggregating
the capital, recurrent and overhead cost of inputs. Theoretically,
economic costs should reflect the opportunity costs of alternative
use of the resources, but practically it is recommended to use
market prices as proxy [21]. Capital costs represent assets used for
more than a year such as equipment, furniture, and recurrent costs
cover personnel, medication, supplies, building use, utilities,
laboratory reagents, and equipment maintenance. The overhead
included costs related to general services shared by other
departments such as support personnel, administration, security,
and other contracted services.
Data collection and analysis
This study was based on primary data collected retrospectively
from different departments within the research programme and
from KDH between February and April 2011. SCD outpatient
clinic utilization data came from the routine data management
system and covered the years 2003 to 2010. The 2010 total cost
was obtained by multiplying the SCD clinic inputs used by their
unit cost. These input data were collected from the three sections
of the outpatient clinic - medical consultation, pharmacy and
laboratory – and the unit costs were obtained from the central
administration, suppliers and local retailers.
The personnel data were collected in two stages: the number,
and position (e.g. the number of clinical officers or laboratory
technicians) came from their respective departments along with
the time spent on SCD outpatient clinic work. Then, the yearly
employer costs corresponding to the employees’ grade and the
mid-range steps were collected from the general administration.
Employer costs included the salary and other benefits such as costs
of employee health insurance and annual leave. Medications
routinely received by children with SCD were stated by the clinical
officer and confirmed by the pharmacist. Unit costs of medications
came from the pharmacy and its procurement unit and the
quantity from the data unit. The supplies costs were calculated
similarly with quantities obtained from the specific department,
and unit market price obtained from the procurement office or
from retailers. The building use cost was included to reflect the
economic cost of space utilization [22] and was based on the rental
price of similar buildings in the hospital neighbourhood reflecting
prevailing market price. The costs of utilities were based on
estimates of average energy use and corresponding costs.
For economic cost of existing equipment, its 2010 replacement
cost was obtained, spread out over useful years of life [21] and
discounted to account for time preference for the present. We
assumed that the equipment had no resale value at the end of its
useful life, set conservatively based on the literature: 5 years for
laboratory equipment and furniture, and 3 years for information
technology equipment [23]. The Kenya short-term Treasury Bond
interest for 3-year (5%) was used for discounting the information
technology equipment and the 5-year rate (7%) for all other
equipment. Assuming the annuity was payable in the beginning of
the year, we used the rate for the years 2 and 4 plus 1, thus
obtaining respectively 2.8594 and 4.3872 as the present value of
USD 1 [21]. The cost of laboratory equipment maintenance was
prorated to the share of its use for the SCD routine clinic.
The research programme provided an overhead cost estimate
ranging from 15% to 20% of the program costs and this study used
17% of the total cost. The total cost based on the inputs was
divided by the number of children seen in 2010 to obtain the mean
cost per child.
All costs were collected in Kenya Shilling (KES) and converted
to US Dollar(USD) using the average of the daily exchange rate
during 2010, i.e., 1 USD=KES 79.261 [24]. We adapted a data
collection tool developed for HIV/AIDS programs [22] written in
Microsoft Excel (Seattle) to organize our data and analysed them
using Stata/SE 10 (College Station).
Sensitivity analysis
We assessed cost following changes in the main underlying
conditions for sensitivity analysis. First, we used the Kenya
Government personnel pay scale rather than that of the research
programme. Second, we used a 3% discount rate as is common in
the literature [23] thus a present value of annuity of USD 1
became 2.9135 and 4.7171 for 3 and 5 years respectively. Third,
we used the range of 10% to 50% for overhead cost as has been
calculated for comparable programs in sub-Saharan Africa and
Kenya [25,26]. Finally, we multiplied the personnel cost by two to
reflect the possibility of two-day clinic considering the number of
patients.
Results
Recruitment and routine care
The Kilifi SCD outpatient clinic is a specialist clinic for children
with SCD. Children were referred to the Kilifi SCD outpatient
clinic from three main avenues. Some children were referred from
other departments within the hospital or different healthcare
facilities in the region. Other children with SCD were identified
through early life screening within the Kilifi Genetic Birth Cohort
study described elsewhere [27]. Finally, siblings of index children
with SCD were screened and if positive referred to this clinic.
Table 1 indicates that the number of children attending this
SCD clinic increased steadily from 119 in 2003 to 402 in 2010.
Paediatric SCD Care Utilization and Costs
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Over this period, a higher proportion of patients (51%–60%) were
male. The Wilcoxon test of equality of the numbers of girls and
boys attending the clinic reject the null and the results is
statistically significant (z =22.524 p= 0.0116). The proportion
of patients in all age groups attending the clinic increased over the
years. In 2010, 38% of the children were 5 years or younger, 35%
were aged 6 to 10 years, and 25% were between 11 and 18. The
remaining 3% were older than 18 years. During 2010, the number
of persons with SCD seen on clinic days varied from 13 to 41
(Figure 1).
Services offered by the SCD outpatient clinic
Children with SCD are scheduled for the SCD routine clinic on
a quarterly basis although they are welcome to visit on a clinic day
if they are sick. The SCD clinic runs once weekly thus occupying
20% of most of the personnel time. The SCD clinic is staffed by a
clinical officer, a trained personnel in charge of data entry and
anthropometric measurement, a phlebotomist, a medical record
officer and a nurse from the general outpatient department. Each
routine visit consists of a medical consultation, including the
recording of anthropometric measurements and vital signs, a urine
dipstick test for protein, glucose, nitrites and blood cells and a
blood draw for additional laboratory tests. These laboratory tests
include a blood film examination for malaria parasites, a full
haemogram, a reticulocyte count and routine biochemistry
(including plasma electrolytes, creatinine and liver function tests).
A prescription for an anti-malarial drug (proguanil) and folic acid
supplement are filled routinely for 3 months.
The SCD clinic exists alongside a general outpatient clinic
where all children regardless of their SCD status receive paediatric
care. The outpatient clinic offers emergency care as well.
Furthermore, children with SCD who visit the hospital for any
complaints on non-clinic days are seen in the general outpatient
clinic.
Economic cost
Table 2 indicates that in 2010, the average total economic cost
per child was USD 138. The economic capital cost amounted to
2,774, the personnel cost 31,329, and the medication amounted to
7,154. The annual costs for supplies were estimated at USD 3,518.
The personnel cost is the single most important component
accounting for 56% of the total expenditures while capital cost
accounted only for 5%. Equipment and building use could be
considered as fixed cost as those inputs cannot be easily changed in
the short run. Using that definition, fixed cost amount for 8% of
the total cost of the clinic. Personnel cost was considered in this
Figure 1. Number of patients seen on clinic days in 2010.
doi:10.1371/journal.pone.0061130.g001
Table 1. Number of children with SCD seen in outpatient
clinic in Kilifi District Hospital by sex 2003 to 2010.
Year Female Male Total
2003 48 71 119
2004 74 79 153
2005 94 106 200
2006 97 116 213
2007 125 145 270
2008 140 163 303
2009 164 186 350
2010 198 204 402
doi:10.1371/journal.pone.0061130.t001
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study as variable. Although changing the personnel would not be
easy in the short run, adjustment was possible by increasing the
number of day spent working in this clinic.
Sensitivity analyses of economic costs
Using the Government of Kenya pay scale instead of KEMRI’s,
the average cost per child would have been USD 94. The
personnel cost would have been USD 16,184, lower than the
personnel cost of KEMRI by 48%. Using a 3% discount rate as
opposed to 7% and 5% had insignificant effects on the economic
cost–it dropped by USD 1 to USD 137 per child—as only the
equipment was discounted. We also used 10% and 50% as
alternate values for the percentage of overhead cost instead of 17%
as in the base case. We obtained the range of USD 130 to USD
177. Finally, the personnel cost was doubled to account for the
high attendance as up to 41 persons visited the clinic on some days
in 2010. The variation provided the highest level of cost per
patient in this study, USD 229.
Discussion and Limitations
The number of patients seen per SCD outpatient clinic session
increased steadily over the years of study and suggests an increase
in the total cost with the number of patients. If the number of
patients recruited kept growing, an increase in personnel and
equipment would become necessary to maintain the quality of
care. Although this SCD outpatient clinic was designed to treat
children, 11 young adults aged 19 to 31 years attended it in 2010.
Most of those young adults were long term clinic attendees while
one attended for the first time at the age of 31 years. The presence
of these young adults hints at the issues of transition that will need
to be addressed as children grow into adulthood in the context of
rare SCD specialized care. More boys than girls attended the SCD
outpatient clinic over the years. Considering that SCD affects a
similar proportion of boys and girls at birth, the higher proportion
of males in this clinic sample leaves an open question about what
happened to girls born with SCD.
We estimated that the overall annual economic cost per child
for the provision of outpatient clinic care for children with SCD at
KDH ranged from USD 94 to USD 229 in 2010. To our
knowledge, ours is the first study that has attempted to quantify the
cost of care provision to patients with SCD in an African hospital.
While the current study focused on the costs relating to the
provision of SCD routine outpatient care, we recognise that this
only represents a small proportion of the total economic cost of
SCD. Other SCD-related medical costs may cover outpatient
items like antibiotic therapy, and emergency care. Note that
pneumococcal vaccine is recommended to children with SCD. In
Kenya, this vaccine is part of the general vaccine schedule for all
children—contrary to the current practice in other countries in
Africa—thus will not be specific to children with SCD. Other
components of the total cost of SCD are inpatient care, non-
medical direct cost (e.g. transportation) and indirect costs.
Examples of indirect costs are missed educational opportunities
Table 2. Economic cost of routine Sickle Cell Disease Clinic, with the main method and sensitivity analyses in USD1.
Input
Main method: Personnel using
KEMRI2 pay scale, 5% discount
for IT equipment and 7% for





















Equipment, furniture 2,774 2,774 2,774 2,774 2,774 2,774
Recurrent costs
Personnel 31,329 16,184 31,329 31,329 31,329 62,658
Medications 7,154 7,154 7,154 7,154 7,154 7,154
Supplies 3,518 3,518 3,518 3,518 3,518 3,518
Utilities 743 743 743 743 743 743




8 8 8 8 8 8
Subtotal excluding
overhead
47,419 32,274 47,228 47,419 47,419 78,748
Overhead3 8,061 5,487 8,029 ,742 23,709 13,387
Total including
overhead
55,480 37,761 55,256 52,160 71,128 92,135
Number of children 402 402 402 402 402 402
Total cost per child 138 94 137 130 177 229
1On average in 2010, all costs in US Dollars (1 USD= KES 79.261 Kenya Shillings).
2KEMRI (Kenya Medical Research Institute)/Wellcome Trust Research Programme.
3Overhead include support personnel, security, general administration and accounting services.
doi:10.1371/journal.pone.0061130.t002
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for children with SCD, and loss of productivity of caregivers and
adults with SCD. Analyses of the total costs attributable to SCD
would be important in the context of African populations and
health systems in which SCD might represent an increasing
burden as economic and demographic transition associated with
global political awareness lead to reduced child mortality. Such
analyses will be the subject of future studies.
The provider-paid costs calculated in this study are attributable
to SCD alone as other staples of paediatric healthcare like
immunizations or anti-helminthic care etc. are not offered through
the SCD clinic but through the general outpatient department.
Without the research programme in Kilifi most of the costs of
specialist care for SCD would be borne by families who can ill-
afford it : 68.5% of the population of Kilifi District live in poverty
[28], healthcare delivered in public facilities is not free for patients,
and health insurance is rare in rural areas. To put costs calculated
in this study into perspective, the Government of Kenya annual
health expenditure per capita was about USD 14 in 2009 (the
latest figures available) [29] or 18% of the lower bound of our
estimates (i.e USD 94). Although provision of this routine care will
help prevent morbidity and mortality, children with SCD in this
population will remain more likely to be hospitalized than other
children. Children with SCD account for 1.6% of all admissions to
the paediatric wards at KDH [30] while the birth prevalence is
only 0.8% in the area. In addition, US-based studies relying on
annual insurance claims have indicated that approximately 40% of
children with SCD incurred at least one hospitalization, about
50% of them visited the emergency department, and SCD-related
medical care costs increased with age [15,16]. While acknowledg-
ing the very different epidemiology and healthcare contexts
between coastal Kenya and the United States, such figures along
with the disproportionate share of SCD related hospitalizations at
KDH suggest that the routine care cost are not the only SCD-
related medical expenditures that those families would face. These
numbers and facts give an insight into likely issues of adherence as
they relate to the medical treatment for a genetic disease in a
resource-constrained environment.
This study has a number of limitations. First, the routine data
on clinic attendance does not distinguish between the scheduled
routine care and the emergency visits so that we could not estimate
if the latter contributed significantly to the high number of patients
on some clinic days. We could not estimate the cost per visit either.
Second, from a methodological perspective calculating the SCD
clinic costs was simpler for separable and discreet inputs such as
the number of pills given to a child, personnel time, and building
use because the clinic was held once a week and occupied specific
personnel and building space. However, this exercise was delicate
for laboratory equipment and supplies and overhead because those
components were not dedicated to children with SCD but served
patients in multiple research programmes concurrently. Second,
although unlikely to be substantial, the cost calculation did not
include buffer stocks for medications and reagents. Finally, land
purchase and building construction was purposefully excluded to
reflect the cost of setting-up a SCD outpatient clinic within an
existing health facility, as was the case at KDH. Such input costs
could be substantial.
To account for the uncertainty related to the limitations, we
conducted a sensitivity analysis varying personnel costs, overhead
costs and equipment discounting rate one at a time. The data was
sensitive to change in the personnel cost –which was the single
highest percentage of the total costs– and that of the overhead.
However, the results were robust to discount rate of equipment.
Future studies will include a careful data collection and analysis of
ingredients for overhead cost to allow apportioning the overhead
based on the programme use.
Conclusion
This study showed that between 2003 and 2010, the number of
unique patients cared for in a provider-paid routine SCD
outpatient clinic increased steadily. Such a rise was concurrent
with a population based early life screening that raised awareness
of the disease, a documented reduction in malaria and other
infectious diseases in the area. A combination of these factors
probably led to a decreased general infant mortality.
The estimated annual cost of routine outpatient care per child
with SCD is USD138 with a range of USD 94 to USD 229 in
2010, with personnel costs representing the single largest
component. Note that costs calculated in this study do include
neither non-SCD outpatient care nor any type of inpatient cost
etc. Thus the average total medical care cost of children with SCD
is higher. Future studies will focus on the other components of the
cost of Sickle Cell Disease. Nonetheless, these figures will provide
African ministries of health and potential donors with an estimate
of the cost for the provision of care to children living with this
condition in similar contexts.
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